Simple blood tests to diagnose compensated advanced chronic liver disease and stratify the risk of clinically significant portal hypertension
Georg Semmler(University of Southern Denmark), Mattias Mandorfer(Medical University of Vienna), Peter Quehenberger, Benedikt Simbrunner(Austrian Academy of Sciences), Lukas Hartl(Medical University of Vienna), Katharina Stopfer(Medical University of Vienna), Bernhard Scheiner(Medical University of Vienna), Annalisa Berzigotti(University of Bern), Yuly P. Mendoza(University of Bern), Elias Laurin Meyer(Statistics Austria), Thomas Reiberger(ERN GUARD-Heart), Benedikt Hofer(Austrian Academy of Sciences), Daniela Neumayer(Medical University of Vienna), Mathias Jachs(Medical University of Vienna), Michael Trauner(Medical University of Vienna), Lorenz Balcar(Medical University of Vienna), L. Fritz(Medical University of Vienna), Robin Szymanski(Medical University of Vienna), Anna Schedlbauer(Medical University of Vienna), Elmar Aigner, Jurij Maurer(Medical University of Vienna), Michael Schwarz(Medical University of Vienna)
Cited by 22
Related Papers
Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA)
|Nature Reviews Gastroenterology & Hepatology|2016|1.4k
NASH limits anti-tumour surveillance in immunotherapy-treated HCC
|Nature|2021|1.3k
Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial
|The Lancet|2019|1.2k
A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis
|New England Journal of Medicine|2016|1.1k